<scp>Cost‐effectiveness</scp> of <scp>first‐line</scp> versus <scp>second‐line</scp> use of domestic <scp>anti‐PD</scp> ‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer-Reference-Cited by-同舟云学术

Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD ‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer

Published:2022-11-13 Issue:6 Volume:12 Page:7389-7397
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Cheng Rihua¹,Zhou Zhen²,Liu Qiao³^ORCID

Affiliation:

1. Department of Pharmacy Brain Hospital of Hunan Province (The Second People's Hospital of Hunan Province) Changsha Hunan China

2. Menzies Institute for Medical Research University of Tasmania Hobart Tasmania Australia

3. Department of Pharmacy The Second Xiangya Hospital, Central South University Changsha Hunan China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5440

Reference34 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

3. Clinicopathologic Features of Advanced Squamous NSCLC

4. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system

5. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial;Expert Review of Pharmacoeconomics & Outcomes Research;2024-07-15

2. Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review;BMC Cancer;2024-03-06

3. A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative;Cancer Medicine;2024-02

4. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China;Risk Management and Healthcare Policy;2023-09

5. Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study;Frontiers in Pharmacology;2023-03-22